


PHARMACEUTICAL 2018

CELGENE CORP DE Rank 50 of 349





PHARMACEUTICAL 2018



CELGENE CORP DE Rank 50 of 349

The relative strengths and weaknesses of CELGENE CORP DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CELGENE CORP DE compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 275% points. The greatest weakness of CELGENE CORP DE is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 109% points.

The company's Economic Capital Ratio, given in the ranking table, is 80%, being 358% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	14,892,000
Cost of Goods Sold	0
Intangible Assets	13,302,000
Liabilities, Current	2,987,000
Liabilities, Non-Current	16,382,000
Other Assets	877,000
Other Compr. Net Income	-102,000
Other Expenses	814,000
Other Liabilities	3,851,000
Other Net Income	105,000
Property and Equipment	1,070,000
Research and Development	5,915,000
Revenues	13,003,000
Selling, General and Administrative Expense	2,941,000

Output Variable	Value in 1000 USD
Assets	30,141,000
Liabilities	23,220,000
Expenses	9,670,000
Stockholders Equity	6,921,000
Net Income	3,438,000
Comprehensive Net Income	3,387,000
Economic Capital Ratio	80%